Amantadine for the Treatment of Refractory Absence Seizures in Children

Area of Science:

• Pediatric Neurology
• Epileptology

Background:

• Childhood epilepsy, particularly typical absence seizures, often responds well to antiepileptic drugs.
• A subset of these patients experience refractory seizures despite standard treatments.
• Investigating novel therapeutic options is crucial for managing drug-resistant epilepsy in children.

Purpose of the Study:

• To evaluate the safety and efficacy of amantadine as an add-on therapy for children with refractory typical absence seizures.
• To assess the clinical and electrographic response to amantadine in this specific pediatric population.

Main Methods:

• A case series involving 4 children with typical absence seizures refractory to at least one year of polytherapy.
• Amantadine was administered at a dosage of 4-6 mg/kg/day.
• Patients were monitored for seizure frequency, clinical improvement, and adverse effects.

Main Results:

• All 4 children achieved complete seizure freedom within one week of initiating amantadine.
• Significant improvement in school performance was observed in the treated children.
• No significant adverse effects were reported during the study period, with seizure freedom maintained for 6-30 months.

Conclusions:

• Amantadine demonstrated promising safety and efficacy as an add-on treatment for pediatric absence epilepsy refractory to multiple antiepileptic drugs.
• The findings suggest amantadine as a viable therapeutic option for this challenging patient group.
• Further multicenter trials are warranted to confirm these results in a larger cohort.